Entero Healthcare Solutions Ltd

Entero Healthcare Solutions Ltd announced a revision in the reappointment tenure for Non-Executive Independent Directors Mr. Rajesh Shashikant Dalal and Ms. Sandhya Gadkari Sharma. This change, approved by the Board of Directors based on the Nomination and Remuneration Committee's recommendation, aims to facilitate effective succession planning and smoother board transitions. The revised tenure is subject to shareholder approval at the upcoming Annual General Meeting. Additionally, the company approved the allotment of 1,475 equity shares under its ESOP 2023 plan.

Entero Healthcare Solutions Ltd announced the outcome of its Board Meeting held on June 26, 2026. The Board approved the allotment of 1,475 equity shares to eligible employees under the Entero Employee Stock Option Plan 2023. Additionally, the Board approved the revised tenure for the reappointment of Independent Directors Mr. Rajesh Shashikant Dalal and Ms. Sandhya Gadkari Sharma for a second term of four years, subject to shareholder approval. The tenure of Mr. Sujesh Vasudevan remains unchanged. The meeting commenced at 1:00 p.m. IST and concluded at 2:45 p.m. IST.

Entero Healthcare Solutions Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Fair Disclosure. The window will be shut effective July 01, 2026, and will reopen 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026. The date for the board meeting to approve these financial results will be communicated separately.

Mr. Kevin Rohitbhai Daftary has resigned as a Non-Executive Nominee Director of Entero Healthcare Solutions Ltd, effective June 12, 2026. The resignation is attributed to increased professional responsibilities and commitments. Mr. Daftary, representing 'Prasid Uno Family Trust', confirmed no other material reasons for his departure. The company will fill the vacancy upon receiving a fresh nomination from the trust.

Entero Healthcare Solutions Ltd announced the grant of 17,500 Employee Stock Options (ESOPs) under its 'Entero Employee Stock Option Plan 2023'. This decision was approved by the Board of Directors based on recommendations from the Nomination and Remuneration Committee. The company also approved the allotment of 3,420 equity shares upon exercise of vested options. The ESOPs have an exercise price of INR 804 per share, with vesting periods ranging from 1 to 4 years and an exercise period of 8 years from vesting. This move is intended to incentivize and retain eligible employees.

Entero Healthcare Solutions Ltd's Board of Directors met on June 11, 2026, approving the allotment of 3,420 equity shares upon exercise of options under the Entero Employee Stock Option Plan 2023. The Board also noted the grant of 17,500 fresh employee stock options under the same plan. The meeting, which lasted from 3:00 PM to 3:50 PM IST, confirmed compliance with SEBI regulations regarding share-based employee benefits. The allotment details include an exercise price of Rs. 804 per share and a premium of Rs. 794, bringing the total issued shares to 4,35,21,597.

Entero Healthcare Solutions Ltd's board approved the grant of 7,300 fresh employee stock options under the 'Entero Employee Stock Option Plan 2023'. The board also approved the re-appointment of independent directors and the allotment of 7,240 equity shares to eligible employees. Additionally, the company will hold its Annual General Meeting on August 19, 2026, via video conferencing. The board also approved the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals.

Entero Healthcare Solutions Ltd's Board approved the re-appointment of M/s. Ernst & Young LLP ('EY') as the Internal Auditor for the financial year 2026-27. The board also approved the re-appointment of Mr. Sujesh Vasudevan, Mr. Rajesh Shashikant Dalal, and Ms. Sandhya Gadkari Sharma as Non-Executive Independent Directors for a second term of five years, subject to shareholder approval. Additionally, the board approved the allotment of 7,240 equity shares to eligible employees under the Entero Employee Stock Option Plan 2023 and noted the grant of fresh 7,300 Employee Stock Options.

Entero Healthcare Solutions Ltd's subsidiary, Sai Pharma Distributors Private Limited, will acquire Vishal Surgicals and Vishal Surgicals & Medicals, a Partnership Firm, through a Slump Sale / Business Transfer Agreement (BTA). The Board of Directors also approved the audited financial results for the quarter and financial year ended March 31, 2026, and re-appointed Mr. Sujesh Vasudevan, Mr. Rajesh Shashikant Dalal, and Ms. Sandhya Gadkari Sharma as Non-Executive Independent Directors. Additionally, the board approved the allotment of 7,240 Equity Shares under the Entero Employee Stock Option Plan 2023 and noted the grant of fresh 7,300 Employee Stock Options.

Entero Healthcare Solutions Ltd's board approved the re-appointment of Mr. Sujesh Vasudevan, Mr. Rajesh Shashikant Dalal, and Ms. Sandhya Gadkari Sharma as Non-Executive Independent Directors for a second term of five years, effective August 25, 2026, subject to shareholder approval. The board also approved the audited financial results for the quarter and financial year ended March 31, 2026. Additionally, the board approved allotment of 7,240 equity shares to eligible employees under the ESOP 2023 plan and noted the grant of fresh 7,300 employee stock options. The 8th Annual General Meeting is scheduled for August 19, 2026. The company also announced the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals through its subsidiary.